Editas licenses new gene-editing tool, raising stakes in drug development race

In a new set of licensing deals disclosed Monday, three-year-old Editas said it obtained exclusive rights to develop therapies based on a genome editing system called CRISPR-Cpf1, discovered by prominent Broad Institute scientist Feng Zhang and colleagues who have applied for patents based on the te...

Full description

Saved in:
Bibliographic Details
Published inBoston Globe (Online)
Main Author Weisman, Robert
Format Newspaper Article
LanguageEnglish
Published Boston Boston Globe Media Partners, LLC 19.12.2016
Subjects
Bosley, Katrine
Competition
Editing
Genomes
Intellectual property
Licenses
Online AccessGet full text

Cover

More Information
Summary:In a new set of licensing deals disclosed Monday, three-year-old Editas said it obtained exclusive rights to develop therapies based on a genome editing system called CRISPR-Cpf1, discovered by prominent Broad Institute scientist Feng Zhang and colleagues who have applied for patents based on the technology. The science is the subject of a long-running intellectual property dispute that's now before a three-judge panel of the US Patent Trial and Appeal Board.